Mylan, Biocon insulin glargine biosimiliar approved in EU and Australia

Mylan N.V. (NASDAQ:MYL) said the European Commission and Australia's Therapeutic Goods Administration each approved Semglee, a biosimilar of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). Mylan co-developed Semglee with Biocon Ltd. (NSE:BIOCON; BSE:BIOCON).

The partners will market the long-acting human insulin analog in 100 unit/mL, 3 mL prefilled disposable pens...